Form 8-K - Current report:
SEC Accession No. 0001193125-25-051072
Filing Date
2025-03-10
Accepted
2025-03-10 17:02:52
Documents
19
Period of Report
2025-03-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d930164d8k.htm   iXBRL 8-K 39358
2 EX-1.1 d930164dex11.htm EX-1.1 281568
3 EX-4.1 d930164dex41.htm EX-4.1 67842
4 EX-5.1 d930164dex51.htm EX-5.1 15704
5 EX-99.1 d930164dex991.htm EX-99.1 12433
9 GRAPHIC g930164g0310095318781.jpg GRAPHIC 3138
10 GRAPHIC g930164g0310130735948.jpg GRAPHIC 2021
  Complete submission text file 0001193125-25-051072.txt   654550

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA beam-20250310.xsd EX-101.SCH 2836
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE beam-20250310_lab.xml EX-101.LAB 17236
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE beam-20250310_pre.xml EX-101.PRE 10803
21 EXTRACTED XBRL INSTANCE DOCUMENT d930164d8k_htm.xml XML 3494
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 857-327-8775
Beam Therapeutics Inc. (Filer) CIK: 0001745999 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39208 | Film No.: 25724654
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)